open access
English
The effect of biotin interference on the results of blood hormone assays [Wpływ interferencji biotyny na wyniki oznaczeń stężenia hormonów we krwi]


- Department of Endocrinology, Centre of Postgraduate Medical Education Bielański Hospital, Warsaw, Poland
- Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland
open access
Abstract
Abstract
Keywords
biotyna; interferencja; immunochemia; suplementy diety; przeciwciała anty-streptowidynowe


Title
The effect of biotin interference on the results of blood hormone assays [Wpływ interferencji biotyny na wyniki oznaczeń stężenia hormonów we krwi]
Journal
Issue
Article type
Review paper
Pages
102-121
Published online
2019-02-22
Page views
5955
Article views/downloads
3811
DOI
10.5603/EP.a2018.0084
Pubmed
Bibliographic record
Endokrynol Pol 2019;70(1):102-121.
Keywords
biotyna
interferencja
immunochemia
suplementy diety
przeciwciała anty-streptowidynowe
Authors
Magdalena Ostrowska
Zbigniew Bartoszewicz
Tomasz Bednarczuk
Klaudia Walczak
Wojciech Zgliczyński
Piotr Glinicki


- Najwyższa Izba Kontroli. Diagnostyka laboratoryjna w Polsce [panel eskpertów. https://www.nik.gov.pl/aktualnosci/organizacja-i-finansowanie-diagnostyki-laboratoryjnej-panel-ekspertow.html.
- Diamandis EP, Christopoulos TK. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem. 1991; 37(5): 625–636.
- Mattman A, Potter M. Approach to the interpretation of unexpected laboratory results arising in the care of patients with inborn errors of metabolism (IEM). Rev Endocr Metab Disord. 2018; 19(1): 5–12.
- Piketty ML, Polak M, Flechtner I, et al. False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences. Clin Chem Lab Med. 2017; 55(6): 780–788.
- Zempleni J, Wijeratne SSK, Hassan YI. Biotin. Biofactors. 2009; 35(1): 36–46.
- Batista MC, Ferreira CES, Faulhaber ACL, et al. Biotin interference in immunoassays mimicking subclinical Graves' disease and hyperestrogenism: a case series. Clin Chem Lab Med. 2017; 55(6): e99–e9e103.
- Gifford JL, Sadrzadeh S, Naugler C. Biotin interference: Underrecognized patient safety risk in laboratory testing. Can Fam Physician. 2018 ; 64(5): 370.
- Piketty ML, Prie D, Sedel F, et al. High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference. Clin Chem Lab Med. 2017; 55(6): 817–825.
- Arya VB, Ajzensztejn M, Appleby G, et al. High-dose biotin in infants mimics biochemical hyperthyroidism with some commercial assays. Clin Endocrinol (Oxf). 2018; 88(3): 507–510.
- Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015; 4(2): 159–169.
- Li D, Radulescu A, Shrestha RT, et al. Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults. JAMA. 2017; 318(12): 1150–1160.
- Samarasinghe S, Meah F, Singh V, et al. Biotin Interference with Routine Clinical Immunoassays: Understand the Causes and Mitigate the Risks. Endocr Pract. 2017; 23(8): 989–998.
- Holmes EW, Samarasinghe S, Emanuele MA, et al. Biotin Interference in Clinical Immunoassays: A Cause for Concern. Arch Pathol Lab Med. 2017; 141(11): 1459–1460.
- Trambas C, Lu Z, Yen T, et al. Characterization of the scope and magnitude of biotin interference in susceptible Roche Elecsys competitive and sandwich immunoassays. Ann Clin Biochem. 2018; 55(2): 205–215.
- Willeman T, Casez O, Faure P, et al. Evaluation of biotin interference on immunoassays: new data for troponin I, digoxin, NT-Pro-BNP, and progesterone. Clin Chem Lab Med. 2017; 55(10): e226–e229.
- Meany DL, Beur SMJ, Bill MJ, et al. A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations. Clinical Chemistry. 2009; 55(9): 1737–1739.
- Kwok JSS, Chan IHS, Chan MHM. Biotin interference on TSH and free thyroid hormone measurement. Pathology. 2012; 44(3): 278–280.
- Wijeratne NG, Doery JCG, Lu ZX. Positive and negative interference in immunoassays following biotin ingestion: a pharmacokinetic study. Pathology. 2012; 44(7): 674–675.
- Minkovsky A, Lee MN, Dowlatshahi M, et al. High-dose biotin treatment for secondary progressive multiple sclerosis may interfere with thyroid assays. AACE Clin Case Rep. 2016; 2(4): e370–e373.
- Kummer S, Hermsen D, Distelmaier F. Biotin Treatment Mimicking Graves' Disease. N Engl J Med. 2016; 375(7): 704–706.
- Henry JG, Sobki S, Arafat N. Interference by biotin therapy on measurement of TSH and FT4 by enzyme immunoassay on Boehringer Mannheim ES700 analyser. Ann Clin Biochem. 1996; 33(Pt 2): 162–163.
- Willeman T, Casez O, Faure P. Biotin in multiple sclerosis and false biological hyperthyroidism: Mind the interference. Rev Neurol (Paris). 2017; 173(3): 173–174.
- Elston MS, Sehgal S, Du Toit S, et al. Factitious Graves' disease due to biotin immunoassay interference — a case and review of the literature. J Clin Endocrinol Metab. 2016; 101(9): 3251–3255.
- Sulaiman RA. Biotin treatment causing erroneous immunoassay results: A word of caution for clinicians. Drug Discov Ther. 2016; 10(6): 338–339.
- Evans N, Yates J, Tobin J, et al. Immunoassay interference secondary to therapeutic high-dose biotin: A paediatric case report. J Paediatr Child Health. 2018; 54(5): 572–575.
- Waghray A, Milas M, Nyalakonda K, et al. Falsely low parathyroid hormone secondary to biotin interference: a case series. Endocr Pract. 2013; 19(3): 451–455.
- US Food and Drug Administration. The FDA warns that biotin may interfere with lab tests: FDA safety communication. https://www.fda.gov/medicaldevices/safety/alertsandnotices/ucm586505.htm.
- Koehler VF, Mann U, Nassour A, et al. Fake news? Biotin interference in thyroid immunoassays. Clin Chim Acta. 2018; 484: 320–322.
- Cusini C, Sassi L, De Paola G, et al. Apparent biochemical thyrotoxicosis due to assay interference by high-dose biotin given for multiple sclerosis. J Endocrinol Invest. 2017; 40(8): 889–890.
- Barbesino G. Misdiagnosis of Graves' disease with apparent severe hyperthyroidism in a patient taking biotin megadoses. Thyroid. 2016; 26(6): 860–863.
- Stieglitz HM, Korpi-Steiner N, Katzman B, et al. Suspected Testosterone-Producing Tumor in a Patient Taking Biotin Supplements. J Endocr Soc. 2018; 2(6): 563–569.
- Lam L, Bagg W, Smith G, et al. Apparent hyperthyroidism caused by biotin-like interference from IgM anti-atreptavidin antibodies. Thyroid. 2018; 28(8): 1063–1067.
- Rulander NJ, Cardamone D, Senior M, et al. Interference from anti-streptavidin antibody. Arch Pathol Lab Med. 2013; 137(8): 1141–1146.
- Brugts MP, Luermans JG, Lentjes EG, et al. Heterophilic antibodies may be a cause of falsely low total IGF1 levels. Eur J Endocrinol. 2009; 161(4): 561–565.
- Vos MJ, Rondeel JMM, Mijnhout GS, et al. Immunoassay interference caused by heterophilic antibodies interacting with biotin. Clin Chem Lab Med. 2017; 55(6): e122–e126.
- Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem. 1999; 45(7): 942–956.
- Heijboer AC, Ijzerman RG, Bouman AA, et al. Two cases of antiruthenium antibody interference in Modular free thyroxine assay. Ann Clin Biochem. 2009; 46(Pt 3): 263–264.
- Chen T, Hedman L, Mattila PS, et al. Biotin IgM antibodies in human blood: a previously unknown factor eliciting false results in biotinylation-based immunoassays. PLoS One. 2012; 7(8): e42376.
- Lam L, Kyle CV. A simple method to detect biotin interference on immunoassays. Clin Chem Lab Med. 2017; 55(6): e104–e106.
- Trambas C, Lu Z, Yen T, et al. Depletion of biotin using streptavidin-coated microparticles: a validated solution to the problem of biotin interference in streptavidin-biotin immunoassays. Ann Clin Biochem. 2018; 55(2): 216–226.